Vascular causes of Alzheimer’s disease: a new therapy approach targeting sEH
Official title: Vascular mechanisms of inhibition of sEH as a novel therapy for AD/ADRD
Funded at University of Mississippi Med Ctr · NIH-11416277 · Data updated 2026-11-12
This grant tests a vascular-based approach to treat Alzheimer’s disease by blocking an enzyme (sEH) to improve brain blood flow and reduce inflammation in people with AD/ADRD.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Mississippi Med Ctr NIH-funded |
| Lab location | 1 site (Jackson, United States) |
| Project start | August 15, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $569,090 |
| NIH project number | 5R01AG079336-03 |
| Project ID | NIH-11416277 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with Alzheimer’s disease or related dementias who may benefit from future vascular-targeted therapies.
✕Less likely to help
The study may not benefit those whose dementia is not linked to vascular factors or who are not suitable for future clinical trials.
What this research studies
If you or a loved one has Alzheimer’s disease or related dementias, this project explores whether a blood vessel–focused treatment can improve brain function by blocking the sEH enzyme. Researchers use animal and molecular studies to understand how sEH inhibitors might restore blood flow and protect brain cells, and they aim to translate those findings toward human therapies. The work builds on evidence that brain blood flow problems contribute to dementia and that similar approaches improved cognition in animal models. This program is led by the University of Mississippi Medical Center and collaborators, with a clear emphasis on how vascular biology affects dementia progression.
Why it matters
Potential benefit: If successful, this could lead to a new treatment strategy that helps preserve thinking and daily function by protecting brain blood vessels in AD/ADRD.
How similar studies have gone: Prior work showing cognitive benefits from sEH inhibitors in AD/ADRD animal models supports a promising direction, though human data remain early.
Where this research is happening
-
University of Mississippi Med Ctr
Jackson, United States Active
Researchers
- Principal investigator: Roman, Richard J. — University of Mississippi Med Ctr
- Study coordinator: Roman, Richard J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.